EntryPoint Capital LLC acquired a new position in shares of Organon & Co. (NYSE:OGN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 27,939 shares of the company's stock, valued at approximately $417,000.
A number of other hedge funds also recently bought and sold shares of OGN. Natixis Advisors LLC lifted its position in shares of Organon & Co. by 7.9% in the 3rd quarter. Natixis Advisors LLC now owns 48,215 shares of the company's stock valued at $922,000 after acquiring an additional 3,520 shares in the last quarter. Commerce Bank lifted its stake in Organon & Co. by 5.5% in the 3rd quarter. Commerce Bank now owns 12,168 shares of the company's stock worth $233,000 after acquiring an additional 637 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Organon & Co. by 35.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company's stock valued at $63,570,000 after purchasing an additional 875,128 shares in the last quarter. Cerity Partners LLC raised its stake in shares of Organon & Co. by 94.0% during the 3rd quarter. Cerity Partners LLC now owns 667,340 shares of the company's stock worth $12,766,000 after purchasing an additional 323,308 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Organon & Co. during the 3rd quarter valued at about $649,000. 77.43% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several research firms recently weighed in on OGN. TD Cowen raised Organon & Co. to a "hold" rating in a research report on Wednesday, January 15th. Barclays reduced their price target on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a report on Friday, February 14th. Finally, Morgan Stanley decreased their price target on shares of Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a research report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $20.80.
View Our Latest Report on Organon & Co.
Organon & Co. Stock Performance
Organon & Co. stock traded down $0.05 on Friday, hitting $14.52. The company's stock had a trading volume of 1,866,865 shares, compared to its average volume of 2,538,684. Organon & Co. has a one year low of $13.87 and a one year high of $23.10. The firm has a market cap of $3.74 billion, a P/E ratio of 4.36, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The company has a fifty day moving average price of $15.33 and a 200-day moving average price of $16.24.
Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. On average, equities analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current year.
Organon & Co. Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were issued a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 7.72%. The ex-dividend date was Monday, February 24th. Organon & Co.'s payout ratio is 33.63%.
About Organon & Co.
(
Free Report)
Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Read More
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
